Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVAS-an interesting california-based biotech company here -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (96)	5/21/2002 8:09:34 PM
From: tom pope	Read Replies (1) \| Respond to of 126

This is the DJ story: Tuesday May 21, 6:02 pm Eastern Time Biotechnology Value Fund Group Has 16.2% Corvas International Stake WASHINGTON -(Dow Jones)- A group including Biotechnology Value Fund L.P. holds a 16.2% stake in Corvas International Inc. , according to a Schedule 13D filed Tuesday with the Securities and Exchange Commission. The group beneficially owns 4.4 million common shares. It purchased shares between March 19 and Tuesday. According to the filing, the group may provide constructive input about the appropriate investment, and rate of investment, of Corvas' cash resources and may assist in various measures intended to preserve and maximize shareholder value, including the exploration of potential strategic alliances, mergers and acquisitions. The group said it doesn't have any current plan to acquire control of Corvas. Corvas is a clinical-stage biopharmaceutical company based in San Diego .